Financials AstraZeneca PLC

Equities

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. 16:35:08 17/06/2024 BST 5-day change 1st Jan Change
12,428 GBX -0.66% Intraday chart for AstraZeneca PLC -1.37% +17.25%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 132,331 131,461 181,878 210,243 209,128 244,466 - -
Enterprise Value (EV) 1 144,340 143,328 206,261 233,166 231,638 265,083 258,511 252,155
P/E ratio 97.9 x 41 x 1,468 x 64.3 x 35.4 x 27.9 x 23.4 x 20.8 x
Yield 2.78% 2.8% 2.44% 2.14% 2.15% 1.95% 2.06% 2.14%
Capitalization / Revenue 5.43 x 4.94 x 4.86 x 4.74 x 4.57 x 4.73 x 4.4 x 4.16 x
EV / Revenue 5.92 x 5.38 x 5.51 x 5.26 x 5.06 x 5.13 x 4.65 x 4.29 x
EV / EBITDA 21.6 x 17.2 x 27.2 x 25.2 x 17.1 x 14.8 x 12.8 x 11.5 x
EV / FCF 72.5 x 37.3 x 42.3 x 26.7 x 25.8 x 30.5 x 21.9 x 18.3 x
FCF Yield 1.38% 2.68% 2.36% 3.74% 3.88% 3.28% 4.57% 5.46%
Price to Book 10 x 8.41 x 4.24 x 5.67 x 5.38 x 5.91 x 5.29 x 4.66 x
Nbr of stocks (in thousands) 1,311,913 1,312,660 1,549,159 1,549,528 1,549,926 1,550,256 - -
Reference price 2 100.9 100.1 117.4 135.7 134.9 157.7 157.7 157.7
Announcement Date 14/02/20 11/02/21 10/02/22 09/02/23 08/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 24,384 26,617 37,417 44,351 45,811 51,685 55,575 58,835
EBITDA 1 6,686 8,311 7,586 9,237 13,580 17,853 20,145 22,018
EBIT 1 6,436 7,340 9,928 13,350 14,534 16,837 19,011 20,694
Operating Margin 26.39% 27.58% 26.53% 30.1% 31.73% 32.58% 34.21% 35.17%
Earnings before Tax (EBT) 1 1,548 3,916 -265 2,501 6,899 11,190 13,197 14,777
Net income 1 1,335 3,196 112 3,288 5,961 8,786 10,450 11,674
Net margin 5.47% 12.01% 0.3% 7.41% 13.01% 17% 18.8% 19.84%
EPS 2 1.030 2.440 0.0800 2.110 3.810 5.661 6.738 7.567
Free Cash Flow 1 1,990 3,838 4,872 8,717 8,984 8,689 11,806 13,758
FCF margin 8.16% 14.42% 13.02% 19.65% 19.61% 16.81% 21.24% 23.38%
FCF Conversion (EBITDA) 29.76% 46.18% 64.22% 94.37% 66.16% 48.67% 58.61% 62.48%
FCF Conversion (Net income) 149.06% 120.09% 4,350% 265.12% 150.71% 98.89% 112.98% 117.85%
Dividend per Share 2 2.800 2.800 2.870 2.900 2.900 3.078 3.244 3.373
Announcement Date 14/02/20 11/02/21 10/02/22 09/02/23 08/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2020 S1 2020 S2 2021 S1 2021 Q4 2021 S2 2022 Q1 2022 Q2 2022 S1 2022 Q3 2022 Q4 2022 S2 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 - - - 12,011 - 11,390 10,771 - 10,982 11,207 - 10,879 11,416 11,492 12,024 12,679 12,574 12,972 13,475 13,410 13,730
EBITDA 1 - - - 1,900 - 2,187 1,896 - 2,579 2,574 - - 3,732 - - - 4,396 4,404 5,260 - -
EBIT 1 - - - 3,318 - 3,961 3,365 - 3,413 2,610 - 3,946 4,291 3,545 2,752 4,310 4,027 4,356 3,974 - -
Operating Margin - - - 27.62% - 34.78% 31.24% - 31.08% 23.29% - 36.27% 37.59% 30.85% 22.89% 33.99% 32.02% 33.58% 29.49% - -
Earnings before Tax (EBT) 1 - - - -636 - 553 247 - 922 778 - 2,262 2,088 1,652 897 2,800 2,361 2,740 3,099 - -
Net income 1 - - - -347 - 386 360 - 1,640 901 - 1,803 1,818 1,378 959 2,179 2,092 2,450 2,493 - -
Net margin - - - -2.89% - 3.39% 3.34% - 14.93% 8.04% - 16.57% 15.93% 11.99% 7.98% 17.19% 16.64% 18.89% 18.5% - -
EPS 2 - - - -0.2200 - 0.2500 0.2300 - 1.050 0.5800 - 1.160 1.170 0.8900 0.6200 1.410 1.341 1.569 1.600 - -
Dividend per Share 2 0.9000 1.900 0.9000 1.970 1.970 - 0.9300 0.9300 - 1.970 1.970 - 0.9300 - 1.970 - 0.8875 0.7750 1.438 0.8750 0.8750
Announcement Date 30/07/20 11/02/21 29/07/21 10/02/22 10/02/22 29/04/22 29/07/22 29/07/22 10/11/22 09/02/23 09/02/23 27/04/23 28/07/23 09/11/23 08/02/24 25/04/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 12,009 11,867 24,383 22,923 22,510 20,618 14,045 7,690
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 1.796 x 1.428 x 3.214 x 2.482 x 1.658 x 1.155 x 0.6972 x 0.3492 x
Free Cash Flow 1 1,990 3,838 4,872 8,717 8,984 8,689 11,806 13,758
ROE (net income / shareholders' equity) 35.6% 36.7% 27.5% 27.2% 29.8% 30% 31.5% 30.6%
ROA (Net income/ Total Assets) 2.19% 4.99% 8.77% 3.26% 11.5% 9.36% 10.6% 11.4%
Assets 1 61,015 64,053 1,277 100,924 51,935 93,902 98,685 102,195
Book Value Per Share 2 10.10 11.90 27.70 23.90 25.10 26.70 29.80 33.80
Cash Flow per Share 2 2.280 3.660 4.180 6.290 6.620 8.540 10.40 11.50
Capex 1 979 961 1,091 1,091 1,361 1,986 1,968 1,937
Capex / Sales 4.01% 3.61% 2.92% 2.46% 2.97% 3.84% 3.54% 3.29%
Announcement Date 14/02/20 11/02/21 10/02/22 09/02/23 08/02/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
157.7 USD
Average target price
174.4 USD
Spread / Average Target
+10.62%
Consensus
  1. Stock Market
  2. Equities
  3. AZN Stock
  4. Financials AstraZeneca PLC
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW